Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • FDA OKs ZIOPHARM Oncology Inc.’s (ZIOP) New Drug Application for DNA-based Therapeutic Candidate 0 comments
    Jun 13, 2011 10:55 AM | about stocks: ZIOP
    ZIOPHARM Oncology Inc., a biopharm company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics, Friday announced that the U.S. Food & Drug Administration (FDA) has accepted the company’s investigational new drug (NYSE:IND) application, giving the company the go-ahead to commence clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate.

    RJ Kirk, Intrexon’s chairman and CEO, and a director of the ZIOPHARM board of directors, said the quick approval of the IND reflects the company’s strength in DNA-based therapeutics in oncology.

    ZIOPHARM is focusing on pursuing the development of novel DNA-based therapeutics for oncology pursuant to an exclusive channel partnership with Intrexon Corporation. The partnership includes two existing clinical-stage product candidates, the first of which is in a phase Ib study (ZIN ATI-00) and the second, entering phase I study.

    The phase I study will evaluate safety as well as immunological and biological effects of ZIN ATI-001in patients with melanoma. In preclinical studies, the immunological mechanism of action of ZIN ATI-001 is similar to ZIOPHARM’s most advanced DNA-based product candidate, ZIN ATI-00.

    ZIN ATI-001 is the second clinical oncology product candidate from ZIOPHARM-Intrexon’s exclusive synthetic biology channel partnership, and according to Kirk, is the first of many products the company anticipates introducing into the clinic.

    Positive clinical data of ZIN-CTI-001 is the first-ever to demonstrate small molecule-controlled production of an anticancer protein in humans; the company recently presented this data at the 2011 Annual Meeting of the American Society of Clinical Oncology.

    For more information visit ziopharm.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
    Stocks: ZIOP
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.